Camber Launches Bexarotene Capsules

Camber Pharmaceuticals, a leader in generic drug approvals and launches, is proud to add Bexarotene Capsules [bex-AR-oh-teen] to its growing portfolio.
Bexarotene Capsules are indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.
Bexarotene Capsules (75mg) are available in 100 count bottles.
To learn more about this product, please visit: www.camberpharma.com/bexarotene
Recent articles
- Camber’s Parent Company, Hetero, Partners with the Gates Foundation to Supply Generic Lenacapavir for HIV Prevention
- Camber Adds 800 mg Darunavir Tablets to Product Family
- Camber Expands Portfolio with 10 New Generic Drug Launches in Q3 2025
- Camber Launches Indomethacin Suppositories
- Camber Launches Voriconazole for Injection
- Camber Launches Magnesium Sulfate Injection